Background {#s1}
==========

Eosinophils are specialized granulocytes able to coordinate multiple pathogenic pathways involved in the allergic, inflammatory and antimicrobial response. Eosinophils arise in the bone marrow and travel to mucosal tissues, where they regulate the local immune response and tissue repair processes ([@B1]). In the gastrointestinal tract, most eosinophils reside in the lamina propria of the stomach and intestines ([@B2]). Under inflammatory conditions, eosinophils accumulate in gut-associated lymphoid tissue ([@B3]) where they promote immune homeostasis ([@B4]) and play an active role against helminths and pathogenic bacteria including *Clostridioides difficile (C. difficile)* intestinal invasion ([@B5]--[@B9]). On the other hand, significant eosinophilic infiltrates of the gastrointestinal mucosa were described in several conditions, including eosinophilic gastrointestinal diseases and to a lesser extend in patients with inflammatory bowel disease ([@B10]) or in those who gradually evolve toward inflammatory bowel diseases ([@B11]--[@B13]). Eosinophilic gastrointestinal diseases comprise a group of rare diseases with a controversial pathogenesis and therapeutic armamentarium. Depending on the location of the eosinophilic infiltrate, eosinophilic gastrointestinal diseases include esophageal, gastric and intestinal disorders. The number of documented eosinophilic gastrointestinal diseases cases is still low, with an estimated prevalence of around 3.3--5.1/100,000 persons ([@B14], [@B15]).

Hence, most data on eosinophilic gastrointestinal diseases derives from only a few hundred case reports ([@B16]--[@B22]). Of these, eosinophilic colitis appear to be a particularly rare entity with a challenging diagnosis ([@B23], [@B24]). Currently, only small case series or single case reports of eosinophilic colitis were reported in literature ([@B14], [@B15], [@B17], [@B25]--[@B28]).

We present the clinical course of a patient with symptomatic eosinophilic colitis who developed nosocomial *C. difficile* infection and sepsis following the diagnostic colonoscopic procedure. The patient displayed an unexpectedly rapid and favorable evolution of these severe infections but also a longstanding improvement of the eosinophilic colitis flare after prompt antibiotic therapy. The article further discusses current literature data on the immunomodulatory role of eosinophils and presents a viewpoint regarding its pathogenic significance in the intestinal inflammatory response in *C. difficile* infection and dysbiosis.

Case Presentation {#s2}
=================

A 64-year old lady was hospitalized in a surgical department for abdominal pain lasting for more than 4 months and accompanied by vomiting, flatulence, fatigue and a 10 kg weight loss, without fever or chills. The patient had a history of asthma with recurrent exacerbations, and negative allergological assessments and had received inhalatory steroids for the past 3-years. The thoracic and abdominal CT examination disclosed diffuse intestinal wall thickening and dilated intestinal loops, sigmoid diverticulosis and a small pleural and pericardial effusion ([Figure 1](#F1){ref-type="fig"}, [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). Superior endoscopy revealed a minimal erythematous gastritis and the colonoscopic evaluation confirmed sigmoid diverticulosis and segmental colitis. Five biopsy specimens were collected for examination during the colonoscopy. No specific yellow nodules, pseudomembranes or other lesions suggestive for *C. difficile* infection were observed during the colonoscopy. Following this procedure, the patient suddenly developed fever and vomiting. The abdominal pain gradually aggravated and the patient developed a severe diarrhea. Given the high probability of an abdominal sepsis, the patient was transferred to the Department of Infectious Diseases.

![Computed tomography of the abdomen and pelvis. Dilated ileal loops (arrowheads).](fmed-07-00328-g0001){#F1}

On admission the patient was febrile (39°C), pale, hypotensive (80/60 mmHg), tachycardic (heart rate 95/min) with a distended painful abdomen, peripheral edema and watery stools. Laboratory parameters displayed an intense inflammatory syndrome, increased liver enzymes, positive procalcitonin, hypoalbuminemia, and anemia secondary to the chronic malabsorption but also hypereosinophilia (twice the normal values) and increased IgE levels (three times higher than the normal values) ([Table 1](#T1){ref-type="table"}). *C. difficile* infection was suspected on the PCR stool assay for toxigenic genes of *C. difficile* (GeneXpert). Blood, stool and urine cultures remained negative. The result of the colonic biopsy was retrieved 48 h after admission and showed a significant eosinophilic infiltrate in the colonic mucosa and submucosa, as well as vasculitis, with numerous eosinophils in the vascular wall. The bioptic specimens did not show any signs of granulomas or malignancy and the histopathologic examination thus pleaded for eosinophilic colitis ([Figures 2A,B](#F2){ref-type="fig"}). Considering the histopathological analysis along with the laboratory and imaging findings, the current presentation was considered as a case of eosinophilic colitis complicated with *C. difficile* infection and sepsis. The patient was initially treated as an abdominal sepsis with ertapenem 1 g/day, with the clinical remission of the fever and the improvement of the laboratory parameters, including the procalcitonin. After receiving the positive results of the PCR stool assay, the patient also received metronidazol 250 mg every 6 h and continued ertapanem for 14 days with a rapid favorable outcome. Upon discharge she was afebrile, asymptomatic, with decreasing IgE levels and normal values of the inflammatory markers. Corticoid treatment was not used during the hospitalization or on discharge. Three months after discharge the patient remained asymptomatic, with no digestive symptoms or asthma exacerbations and normal laboratory values except for persistent hypereosinophilia. The patient also exhibited increasing values of the eosinophils in the following 6 months, raising concerns of a malignant proliferation. She was then admitted to a hematology unit and later to a gastroenterology ward and was placed on corticosteroid treatment with favorable results. On follow-up the patient remained asymptomatic, with no relapse within the following 3-years. The eosinophil count gradually decreased, yet remained at the upper normal limit until now.

###### 

Laboratory investigations in a case of eosinophilic colitis complicated with *C. difficile* infection and sepsis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Laboratory findings**                                                                                    **Reference range**                                                                                                                                                                                                    **Day 1**                                                  **Day 3**   **Day 5**   **Day 7**   **Day 90**   **Six months later**   **Three-years later**
  ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------- ----------- ----------- ------------ ---------------------- -----------------------
  White blood cells (cells/mm^3^)                                                                            3.9--9.6                                                                                                                                                                                                               9.1                                                        10.3        9.5         7.9         10           20.38                  9.85

  Neutrophil granulocytes (cells/mm^3^)                                                                      1.4--6.5                                                                                                                                                                                                               5.1                                                        3.53        3.7         3.8         6.5          12.02                  4.37

  Eosinophils (cells/mm^3^)                                                                                  0--0.7                                                                                                                                                                                                                 1.8                                                        3.39        3.2         1.95        2.2          2.59                   0.81

  Lymphocytes (cells/mm^3^)                                                                                  1.2--3.4                                                                                                                                                                                                               0.9                                                        1.86        1.7         1.6         0.8          4.41                   3.88

  Hemoglobin\                                                                                                12--17.2                                                                                                                                                                                                               8.6                                                        7.8         8.5         8.5         12           11.4                   13.3
  g/dL                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Thrombocytes (cells/mm^3^)                                                                                 200--400                                                                                                                                                                                                               397                                                        442         480         532         483          478                    328

  Erythrocyte sedimentation rate (mm/h)                                                                      \<36                                                                                                                                                                                                                   110                                                        100         70          36          16           48                     

  Fibrinogen (mg/dL)                                                                                         200--393                                                                                                                                                                                                               782                                                        750         494                     320                                 

  C-reactive protein (mg/L)                                                                                  0--3                                                                                                                                                                                                                   280                                                                                                         16.9                   

  Procalcitonin (ng/mL)                                                                                      Absent                                                                                                                                                                                                                 0.65                                                       0.50        0.14        \<0.05      0                                   

  Ig E (UI/mL)                                                                                               0--295                                                                                                                                                                                                                 956                                                        --          --          --          300          1,356                  

  IgG (g/L)                                                                                                  7--16                                                                                                                                                                                                                  12.2                                                                                                                               

  IgM (g/L)                                                                                                  0.4--2.3                                                                                                                                                                                                               0.85                                                                                                                               

  IgA (g/L)                                                                                                  2.78                                                                                                                                                                                                                   2.78                                                                                                                               

  Complement C3/C4 (g/L)                                                                                     0.7--1.75/\                                                                                                                                                                                                            1.11/0.3                                                                                                                           
                                                                                                             0.15--1.8                                                                                                                                                                                                                                                                                                                                                 

  Hepatitis B, C, HIV tests                                                                                                                                                                                                                                                                                                         Negative                                                                                                    Negative               

  ALT (U/L)                                                                                                  9--52                                                                                                                                                                                                                  41                                                                                                          57                     

  Lipase (U/L)                                                                                               23--300                                                                                                                                                                                                                297                                                                                                                                

  Glucose (mg/Dl)                                                                                            65--105                                                                                                                                                                                                                97                                                                                                          84                     

  Creatinine (mg/Dl)                                                                                         0.7--1.2                                                                                                                                                                                                               0.7                                                                                                         0.84                   

  Serum albumin (g/Dl)                                                                                       3.5--4.1                                                                                                                                                                                                               1.74                                                       1.60        2.07        2.53        4.1          3.4                    

  Blood culture (aerobic/anaerobic), Uroculture,\                                                                                                                                                                                                                                                                                   Negative                                                                                                                           
  Stool culture[^\*^](#TN1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                       

  Stool microscopic examination including\                                                                                                                                                                                                                                                                                          Negative for ova, parasites, leucocytes, yeast and molds   Negative                Negative                 Negative               
  stool for ova or parasites                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Stool culture for Strongyloides stercoralis                                                                                                                                                                                                                                                                                                                                                                                                   Negative               

  Toxoplasma gondii IgG                                                                                                                                                                                                                                                                                                                                                                                                                         Negative               

  Toxocara canis IgG                                                                                                                                                                                                                                                                                                                                                                                                                            Negative               

  Trichinella spirallis IgG                                                                                                                                                                                                                                                                                                                                                                                                                     Negative               

  C difficile tcdA and tcdB genes (stool, PCR, GeneXpert)                                                                                                                                                                                                                                                                           Positive                                                                                                                           

  Food alergens (IgE detection)                                                                                                                                                                                                                                                                                                     Negative                                                                                                    Negative               

  Serum autoimmunity markers (Eneasystem III test)[^\*\*^](#TN2){ref-type="table-fn"}and rheumatoid factor                                                                                                                                                                                                                          Negative                                                                                                    Negative               

  Bone marrow aspiration (6 months later)                                                                    Cytologic smear: 42--44% eosinophils, with cells in all stages of maturation                                                                                                                                                                                                                                                                              

  Bone marrow biopsy                                                                                         Myeloid hyperplasia with 50--55% eosinophils; no *cellular atypia*                                                                                                                                                                                                                                                                                        

  (6 months later)                                                                                           Immunohistochemical tests: CD34 positivity \<5% (isolate cells); CD68/PG-M1 positivity (only isolate monocytes); tryptase expression positive only in a few mast cells; CD3 positivity in rare *small* T lymphocytes                                                                                                                                      

                                                                                                             Genetic tests: *BCR-ABL1* gene sequence: negative (multiplex PCR)                                                                                                                                                                                                                                                                                         

                                                                                                             *FIP1L1-PDGFRA* and *PDGFRB* fusion gene: negative expression                                                                                                                                                                                                                                                                                             

                                                                                                             Conclusion. There are no specific *immunohistochemistry* or genetic aberrancies for eosinophilia-associated myeloproliferative neoplasms                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Stool culture (Shigella, Salmonella, Yersinia, enteroinvasive, E coli serotypes)*;

*ANA Screen, dsDNA, ssDNA, Anti SS-A (Ro),Anti-SS-B (La), Anti Sm, Anti Jo, Anti SCL-70, AntiCentromer, p-ANCA, cANCA, Antiglyadin IgA, IgG, Antitransglutaminase IgA, IgG, Mitochondrial antigen AMA- (Eneasystem III test)*.

![Eosinophilic colitis, histological section. Photography with objective at **200X**. Biopsy was fixed in formalin, embedded in paraffin and stained with hematoxylin-eosin. **(A)** Colonic mucosa with numerous eosinophils infiltrating the lamina propria, of which some with an intraepithelial localization. Polymorphonuclear leukocytes and eosinophils are also seen infiltrating the muscularis mucosa. **(B)** Numerous eosinophils infiltrating the colonic submucosa.](fmed-07-00328-g0002){#F2}

Discussion {#s3}
==========

Eosinophilic colitis is a rare and insufficiently characterized disease. The clinical presentation of eosinophilic colitis is highly unspecific and prompts a very wide differential diagnosis, which includes inflammatory bowel diseases, celiac diseases, neoplasia, vasculitis, the hypereosinophilic syndrome, drug induced colitis or various infectious etiologies ([@B28]). Currently, the only definitive criteria for eosinophilic colitis is the finding of an extensive eosinophilic infiltrate of the intestinal wall, containing at least 30 eosinophils per high-power field in at least five high-power fields associated with endoscopic abnormalities ([@B29], [@B30]). However, the histopathologic criteria are not standardized and differ between studies ([@B22], [@B23], [@B31]--[@B33]). Thus, in the absence of characteristic clinical and laboratory findings, many patients could remain undiagnosed ([@B23]). The underlying pathophysiologic mechanisms in eosinophilic colitis have not been fully elucidated and the therapeutic options are limited. Allergic mechanisms appear to play an important, albeit unknown role in a large number of patients and consequently the use of corticosteroids in severe cases is considered beneficial ([@B16], [@B18], [@B30]). An atopic state has been reported by various authors in 41.8% of patients with eosinophilic colitis ([@B14]). However, its presence is not mandatory ([@B18], [@B34]) and IgE--mediated mechanisms appear to be more common in young patients compared to adults ([@B35]). Peripheral eosinophilia was observed in 74--83.3% of cases with eosinophilic colitis and has been associated with a high rate of relapse ([@B18], [@B20], [@B26]). Still, serum eosinophilia was not recorded in all cases. Various authors have underlined the absence of a correlation between serum eosinophilia and the colitis outcome or the intestinal eosinophilic infiltrate, thus suggesting the secondary role of eosinophilia in the onset of colitis ([@B36], [@B37]).

Clinical and experimental studies have showed that the trafficking of eosinophils to the gut and their activation is stimulated by intestinal signals released by the intestinal epithelia, as well as by type 2 innate lymphoid cells (ILC2) or by mucosal immune response ([@B38]--[@B40]). Hence, murine studies showed that eosinophils normally accumulate in the lamina propria of the gut and stomach and their presence is mainly regulated by eotaxin-1, a chemokine released by epithelial cells ([@B38], [@B40]). Eotaxin expressed throughout the gastrointestinal tract displays a synergism with IL-5 and IL-13, two ILC2- secreted cytokines ([@B39], [@B40]). Other potent regulators of tissue eosinophilia and ILC2 activity include the cytokines IL-25 (a member of the IL-17 family) and IL-33 (a member of the IL-1 family), two central mediators of the Th2 immunity and Foxp3(+) regulatory T (Treg) cells immunosuppressive activities of the gut barrier ([@B41], [@B42]). Thus, the intestinal trafficking of eosinophils is a result of the signals released by the intestinal barrier and of the immune mediators regulated by various physiologic or pathologic stimuli.

The Immunomodulatory Role of Eosinophils in the Intestinal Inflammatory Response
--------------------------------------------------------------------------------

The ILC2-eosinophil axis plays a major role in the specific anti-inflammatory response to allergen exposure as well as in the protective immunity against pathogens and the remodeling and intestinal repair ([@B43]--[@B45]). Eosinophils constitutively express various toll like receptors which enable the recognition of numerous microbial antigens, sustain secretory IgA production, dendritic cells activation and Th1/Th17 pro-inflammatory response as well as the retention of immunosuppressive Treg cells in the lamina propria ([@B4], [@B46], [@B47]). Thus, eosinophils display both a pro-inflammatory and a cytotoxic potential against pathogenic germs, while also supporting a protective role in gut homeostasis. In studies on healthy mice, intestinal eosinophils preserve the integrity of the epithelial barrier and also regulate the innate host defense and tissue remodeling ([@B4], [@B48]--[@B51]).

Nevertheless, ILC2-Th2 secreted cytokines and intestinal eosinophils have been linked with significant histopathological changes during eosinophilic esophagitis or other intestinal disorders ([@B2], [@B44], [@B52], [@B53]). Still, there is insufficient data regarding the conditions which facilitate this phenotypical switch of eosinophils and which enable their extensive and chronic infiltration of the colonic wall. The changes of the intestinal environment and the pathologic transformation of tissue eosinophils have been associated with multiple factors such as a genetic predisposition, various intestinal allergens, as well as with persistent intestinal infections or severe and prolonged dysbiosis ([@B54]--[@B57]). Nevertheless, the pathologic role of intestinal eosinophils during dysbiosis or enteral infections such as *C. difficile* remains controversial ([@B58]--[@B60]).

Intestinal Eosinophils and *C. difficile* Infection
---------------------------------------------------

The number of cases with *C. difficile* infection-associated eosinophilic colitis is extremely small. Kim et al. published a similar case ([@B61]). None of the existing prevalence studies have approached the impact of the intestinal eosinophilic infiltrate on the colonization with *C. difficile* strains. However, the role of intestinal eosinophils in the attenuation of the inflammatory immune response during *C. difficile* infection was underlined by Buonomo and other authors and was attributed to the mucosal eosinophilia ([@B6], [@B62]--[@B64]) and IL-25 induction. Additionally the previous studies also discussed the role of IL-33, in the recruitment of eosinophils ([@B65]) and ILC2 activation ([@B45]), in the maintenance of intestinal eubiosis ([@B50]) or in the reduction of *C. difficile* mortality ([@B45]). In this respect, most murine models highlighted the ability of IL-33 to orchestrate the inflammatory response and tissue remodeling, further leading to a subsequent decrease in the translocation of pathogenic bacteria ([@B66]--[@B68]) and to the preservation of the intestinal homeostasis ([@B66], [@B68]). Hence, the IL-25/IL-33/ILC2 axis activation and gut eosinophils regulate the local immune response during acute enteral infections and play a specific regulatory role in inflammatory response during *C. difficile* infections ([@B45]). At the same time, IL-33 remains a contradictory cytokine with a marked pro-inflammatory potential ([@B69], [@B70]). Hence, a high and persistent level of IL-33 could contribute to an excessive eosinophilic response and to the build- up of pathogenic lesions. Nevertheless, the previous hypotheses require further clinical validation and if proven could significantly change the current perspective on the role played by intestinal eosinophils in the pathogenesis of intestinal inflammatory diseases.

Intestinal Eosinophils and Microbiota Homeostasis
-------------------------------------------------

The microbiota plays a remarkable anti-infectious role, enabling the survival of commensal germs and the elimination of pathogens as a result of its connections with the intestinal immunity and the intestinal epithelia. The immune-microbiota homeostasis is closely linked to the eosinophilic immune response, explaining the rapid activation of the latter during dysbiosis ([@B4]). Regarding the underlying pathogenic mechanisms, both enteral infections and related dysbiosis increase the concentration of intestinal eosinophils through a Th17- pro-inflammatory response, as well as through the ILC2-eosinophil axis which ensues after the epithelial release of IL-25/IL-33 cytokines ([@B71]).

Once stimulated, the intestinal eosinophils exert an important immunomodulatory role, regulating the excessive inflammatory response ([@B72]). This regulatory role involves the suppression of the Th17 response elicited by IL-1 receptor antagonist IL-1 Ra, the activation of CD103+ dendritic cell activation, the differentiation of Treg cells and the synthesis of secretory antimicrobial IgA ([@B47], [@B50], [@B73], [@B74]). Eosinophils are thus involved in the preservation of the intestinal homeostasis and are correlated with the composition of the intestinal microbiota, as shown experimentally by Chu et al. ([@B4]) and Jung et al. ([@B50]).

Chu et al. ([@B4]) analyzed the microbiota of eosinophil-deficient mice and recorded various significant differences, most of which concerned segmented filamentous bacteria, a member of Clostridiales with an essential role in the Th17 induction of and T cell response ([@B75], [@B76]). At the same time, Jung et al. ([@B50]) showed that the lack of gastrointestinal eosinophils reduces the level of secretory IgAs and decreases the ensuing protection against microbial pathogens, leading to dysbiosis. These experiments support the ***L***ocal ***I***mmunity ***A***nd/or ***R***emodeling/***R***epair (LIAR) hypothesis ([@B51]) formulated by Lee in 2010 according to which in a Th1/Th17 polarized microenvironment, the intestinal eosinophilic infiltrate is a regulatory and not a destructive event, an effect, rather than a cause of the intestinal inflammation. Hence, its presence in a severe illness ([@B10]) could be an adaptation mechanism to antigenic exposure meant to attenuate the Th17 immune response and to favor tissue regeneration.

Notable Findings of the Clinical Case
-------------------------------------

The case discussed above displayed several notable features regarding its diagnosis and evolution.

For one thing, the patient reported a non-specific onset which initially suggested an abdominal tumor, given the diffuse abdominal pain and the accompanying weight loss in the past 4 months However, the subsequent histopathological exam disclosed numerous eosinophils located in the lamina propria of colonic mucosa and muscularis mucosa, accompanied by hypereosinophilia and an increased IgE serum level, which supported the final diagnosis of eosinophilic colitis. Furthermore, the disease was considered severe based on the extension of the eosinophilic infiltrates, the prolonged diseases course and hypoalbuminemia and anemia secondary to the colonic malabsorption ([@B36]).

Secondly, the diarrheal syndrome was interpreted in the context of a *C. difficile* infection, according to the case definitions elaborated by the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The diagnosis of *C. difficile* infection was based on the following arguments: (a) the sudden debut of a diarrheal syndrome following colonoscopy; (b) the positive PCR assay indicating *C. difficile* toxin genes *tcdA* and *tcdB;* (c) the absence of other causes explaining the diarrheal syndrome ([Table 1](#T1){ref-type="table"}); (d) the therapeutic response to oral vancomycin.

Regarding the risk of colonization with toxigenic strains of *C. difficile*, while this alternative is possible in asymptomatic patients, we argue that this is less likely given the sudden development of a diarrheic syndrome in our patient in the absence of other causes ([Table 1](#T1){ref-type="table"}) or of known risk factors for *C. difficile* colonization ([@B77], [@B78]).

Data regarding the risk of colonization with toxigenic strains of C. difficile remains controversial. While no data are available on *C. difficile* colonization in patients with eosinophilic colitis, Cowardin et al. showed in a mouse model of *C. difficile* colitis that toxigenic strains inhibit the protective eosinophilic response through a TLR2 mediated mechanism and favor the inflammatory response and the development of diarrhea ([@B62]). Nevertheless, the hypothesis of a toxigenic colonization before colonoscopy cannot be disproved. Given the preexistent inflammatory lesions it is probable that such a colonization would have induced a previous episode of *C. difficile* infection ([@B78]) which did not occur.

The colonoscopy also exposed the patient to supplementary complications. The risk of *C. difficile* infection after colonoscopy has been previously suggested ([@B79], [@B80]) and it is considered a rare occurrence. Nosocomial *C. difficile* strains exhibit high cytotoxicity and higher rates of recurrence and bloodstream infections ([@B81]). The occurrence of *C. difficile* infection in cases of inflammatory bowel disease leads to the activation of pro-inflammatory cytokines, including the IL-1β/Th17 axis ([@B78]) which aggravates the course of diseases ([@B82]--[@B85]), increases the risk of *C. difficile* recurrences ([@B84]) and raises the mortality by four times ([@B86]). Similarly the risk of sepsis in *C. difficile* infection is a severe event due to the altered intestinal barrier and the subsequent bacterial translocation ([@B87], [@B88]).

Nevertheless, in our case the patient displayed a favorable and unexpectedly rapid evolution, along with the significant improvement of the symptoms of eosinophilic colitis following antibiotic treatment.

The evolution of our case is compatible with a protective role of eosinophils toward *C. difficile*-associated infection as suggested by Buonomo et al. ([@B6]) and Cowardin et al. ([@B62]) as well as a beneficial role of eosinophils in gut homeostasis discussed by Jung et al. ([@B50]) and Chu et al. ([@B4]).

Our case also underlines the role of dysbiosis and the impact of its treatment on the flare of eosinophilic colitis. The clinical outcome of the patient suggested that the intestinal dysbiosis remitted; had the dysbiosis persisted it would have aggravated under ertapenem and the infection with *C. difficile* would have recurred. The rapid improvement without a recurrence was particularly intriguing: an antibiotic treatment in a patient with eosinophilic colitis resolved both the *C. difficile* infection and alleviated the manifestations of eosinophilic colitis. In other words, if the gut equilibrium between pathogens and commensals is re-established, the clinical course of intestinal inflammatory diseases should also improve, as has been shown by Khan et al. ([@B89]). Hence, it is possible that this finding could also apply to eosinophilic colitis, an intestinal inflammatory disease.

It is probable that the chronic inflammatory response in the eosinophilic colitis is maintained through either occult intestinal infections and related dysbiosis or through an abberant immune response to the intestinal microbiota, two key events which could favor the intestinal acummulation of eosinophils. Should this be the case, it is probable that the administration of synbiotics, fecal transplantation or other regulatory therapeutic agents of microbiota could address both the inflammatory response and dysbiosis. Hence, Dai and colleagues reported a severe case of eosinophilic gastroenteritis, with a rapid remission following fecal microbiota transplantation and glucocorticoid treatment ([@B90]). However, the role of dysbiosis in the exacerbation of the intestinal immune response and in the pathogenesis of intestinal inflammation has already been shown in experimental studies ([@B91]), in patients with inflammatory bowel disease ([@B92], [@B93]) and in various murine experiments ([@B94], [@B95]). This finding has led to an increased interest for therapeutic fecal transplantation in inflammatory bowel disease ([@B96]--[@B98]), although its indication has not been formally studied in eosinophilic colitis ([@B99]). Additional research is needed to establish the impact of therapeutic strategies against dysbiosis on the clinical outcome of eosinophilic colitis.

The Significance of the Case
----------------------------

The study of gut dysbiosis in eosinophilic colitis was not previously approached although similar correlations have been observed in other intestinal inflammatory syndromes ([@B100], [@B101]). The importance of this case lies in a clinical hypothesis to be proven by future studies, regarding the correlation between eosinophilic colitis and intestinal dysbiosis. At the same time, we wanted to highlight that current results from experimental data support the physiopathological hypothesis of eosinophils as defense cell-lines attracted to the intestinal mucosa in order to maintain intestinal homeostasis. Hence, the presence of eosinophils in the gut indicates a previous intestinal "conflict," potentially due to a shift of the harbored intestinal flora. If proven, this concept could enable a more simple, less expensive and less aggressive treatment which could potentially be implemented in eosinophilic colitis as well as in other intestinal inflammatory diseases. The publication of other cases could be useful for the understanding of other physio-pathological aspects in eosinophilic syndromes.

Conclusion {#s4}
==========

The current case describes an uncommon gastrointestinal disorder- eosinophilic colitis---complicated by nosocomial *C. difficile* infection and severe sepsis following a diagnostic colonoscopy. Moreover, the rapid and intriguing improvement of colitis after antibiotic treatment underlines the relevance of restoring the intestinal eubiosis in order to achieve the remission of both the infectious complications and the flare of eosinophilic colitis.

The case additionally highlights the role of eosinophils in the protection of the intestinal barrier and intestinal immune response during *C. difficile* infection and reveals how the reestablishment of the microbiota homeostasis leads to a favorable evolution of eosinophilic colitis.
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Computed tomography of the abdomen and pelvis. Mild circumferential and diffuse intestinal wall thickening with parietal enhancement (arrows).
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